Hi again from the Canna Oils team. Yes, there is such a thing as being Endocannabinoid Deficient, and it just may explain why some conditions are very hard to treat.
What is Clinical Endocannabinoid Deficiency?
Clinical Endocannabinoid Deficiency (CECD) is a condition where an individual produces a lower amount of cannabinoids than experts consider to be essential in the promotion of health, vitality, and well-being.
Scientists now believe CECD may play a role in the following conditions:
- Irritable Bowel Syndrome (IBS)
- Multiple Sclerosis (MS)
- Post-Traumatic Stress Disorder (PTSD)
- Motion Sickness
There are a lot of questions when it comes to the ECS – that’s short for endocannabinoid system. But not a lot of answers.
That’s because the ECS wasn’t discovered until recently. In fact, it wasn’t until the late 1980s that the ECS was discovered through a government-funded study at St. Louis University School of Medicine.
But like with any other biological systems, there are instances where it doesn’t work as generally as it would and result in issues such as endocannabinoid deficiency syndrome. Research is continually shuffling through the complexities of the ECS – discovering how some issues result when our bodies don’t produce enough endocannabinoids for the ECS. Otherwise known as endocannabinoid system deficiency.
First proposed by Dr. Ethan Russo in 2001, the clinical endocannabinoid deficiency (CECD) theory implies that because of various factors, the body results in an endocannabinoid system deficiency.
It’s a theory based on neurotransmitter deficiencies that can cause even more underlying problems. In a published study from 2004, Dr. Russo explores the concept of CECD and details how:
“Migraine, fibromyalgia, IBS and related conditions display common clinical, biochemical and pathophysiological patterns that suggest an underlying clinical endocannabinoid deficiency…”
This idea suggests that through a lack of proper endocannabinoid production, or an endocannabinoid deficiency, further issues may ensue. Because the ECS can be a critical part of numerous bodily functions, including sleep, mood, clarity, and much more, endocannabinoid deficiency can cause problems that result in lingering issues.
His endocannabinoid deficiency syndrome research shows that any alterations that affect varying levels of endocannabinoids – either through the destruction and failure in production or the weakening and strengthening of cannabinoid receptors – can influence its regulatory capabilities for several functions.
It’s a very interesting subject, and might just be a “light bulb” moment for many of us. As we know, Canna Oils BCP (Beta Caryophyllene) is a phytocannabinoid (cannabinoids that come from plants) and makes a great supplement for our Endocannabinoid System (ECS). Canna Oils BCP is an CB2 receptor antagonist and can assist our ECS to get back into “balance” whether we are clinically deficient or not. From what I have researched, we ALL can benefit from supplementing our ECS!!
Check out previous blogs for more information on the ECS it’s Receptors.
Next time we will look at what are the causes of CECD – don’t miss it!
The above information is for educational purposes only – not intended as medical advice.